UCL CANCER DOMAIN

UCL



UCL Cancer Symposium

Wednesday 1 May 2024

www.ucl.ac.uk/research/domains/cancer

Welcome

Dear colleagues,

We are excited to welcome you to the 2024 UCL Cancer Symposium, the UCL Cancer Domain's annual flagship event.

Our overarching theme "Cancer: The Next Generation" points to the future of research, therapy, and prevention, and UCL's increasing strength and leadership across the field. The theme also refers to the prominence of childhood cancer in UCL's portfolio, the focus of a terrific afternoon session today. The impressive range of talks throughout the day showcase UCL's expertise in so many disciplines: molecular and cellular biology, genetics, clinical research and biological therapy, advanced computation and AI, mathematics, health data, technology, and the built environment. An extraordinary and probably unique range of specialties, all bearing down on cancer, and brought to you in a single event.

We are delighted to open the Symposium with our Keynote, Professor Charles Swanton. Charlie is Chief Investigator of the groundbreaking CRUK TRACERx study, and his work has transformed our understanding of genomic diversity within cancers, how tumours evolve over space and time, and the impact of that diversity on immune surveillance and clinical outcomes.

Our Cancer Early Careers Network brings you the poster presentation in the hall. Posters are an excellent opportunity for junior researchers to show their work and make new connections. Please take the time to view posters during the breaks and capitalise on the networking opportunity.

As always, we would like to thank the sponsors for making the event possible. Please do visit the commercial sponsor desks and take advantage of the valuable session from our major sponsor Stratech at lunchtime, which focuses on the use of secondary antibodies in immunoassays.

Finally, a special mention: This year Professor Tariq Enver is stepping down as Director of the UCL Cancer Institute. Tariq has had an enormous impact on UCL's cancer research profile, taking the Cancer Institute to its dominant position in the UK and internationally. We would like to take this opportunity to thank him for his leadership and wish him well with whatever comes next.

We look forward to seeing you and hope you enjoy the day,

Professor Nicholas Greene, UCL Great Ormond Street Institute of Child Health

Professor Daniel Hochhauser, UCL Cancer Institute

Professor Alison Lloyd, UCL Laboratory of Molecular Cell Biology

Professor Gary Royle, Department of Medical Physics & Biomedical Engineering

Programme

09:00 – 09:30	**Registration**
09:30 – 09:35	**Welcome and introductions**
	Daniel Hochhauser, Professor of Medical Oncology, Research Department of Oncology, UCL Cancer Institute; Co-Chair, UCL Cancer Domain
09:35 – 10:20	**Keynote talk**
	Chair: Daniel Hochhauser
	Charles Swanton, Chair in Personalised Medicine, Research Department of Oncology, UCL Cancer Institute **Cancer evolution**
10:20 - 12:40	**Session 1**
	Chair: Alison Lloyd, Professor of Cell Biology, Director of UCL Laboratory for Molecular Cell Biology; Co-Chair, UCL Cancer Domain
10:20 - 10:45	**Maria Secrier, Associate Professor in Computational Cancer Biology, Department of Genetics, Evolution and Environment, UCL** **Cell state switches and local adaptation in cancer: insights from single cell and spatial data**
10:45 - 11:10	**Kasper Fugger, Group Leader - UCL Cancer Institute and Visiting Scientist, Francis Crick Institute** **Detoxification of non-canonical nucleotides is essential to safeguard genome stability**
11:10 - 11:40	**Poster session & tea and coffee**
11:40 - 12:05	**Marnix Jansen, Clinical Professorial Research Fellow, Research Department of Pathology, UCL Cancer Institute** **Switch it up: Mutation rate evolution drives immune escape in mismatch repair-deficient cancer**
12:05 - 12:30	**Brieuc Lehmann, Lecturer (Assistant Professor), Department of Statistical Science, UCL** **Cancer inequalities: challenges and opportunities for data science**

12:30 - 12:40	**Early career network co-chairs address, Dr Pilar Acedo and Dr Ilona Kubajewska**
12:40 – 13:50	**Lunch break, poster session**
13:20 – 13:40	**Workshop by Stratech (major sponsor): Optimising your immunoassay with secondary antibodies**
13:50 – 15:05	**Session 2**
	Chair: Nicholas Greene, Professor of Developmental Neurobiology, Developmental Biology and Cancer Department, UCL GOS Institute of Child Health
13:50 - 14:15	**Tariq Enver, Director, UCL Cancer Institute; Cancer Lead, UCLP AHSC; Lead, CRUK City of London Centre** **Initiation and evolution of childhood leukaemia**
14:15 - 14:40	**J.P. Martinez-Barbera, Professor of Developmental Biology and Cancer, Developmental Biology & Cancer Department, UCL GOS Institute of Child Health** **Tumour promoting activities of senescent cells in cancer**
14:40 - 15:05	**Sara Ghorashian, Developmental Biology & Cancer Department, UCL GOS Institute of Child Health** **Towards optimal CAR-T cell therapies for acute leukaemia**
15:05 - 15:35	**Poster session & tea and coffee**
15:35 – 17:15	**Session 3**
	Chair: Rebecca Shipley OBE, Professor of Healthcare Engineering, Department of Mechanical Engineering; Director, Institute of Healthcare Engineering
15:35 - 16:00	**Karen Page, Professor of Mathematical Biology, Department of Mathematics** **Mathematical models of CAR-T cell cancer therapy**

16:00 - 16:25	**Steve Harris, Principal Clinical Research Fellow, Clinical Epidemiology, UCL** **Multi-modal data access at UCLH**
16:25 - 16:50	**Grant Mills, Professor of Healthcare Infrastructure Delivery, The Bartlett School of Sustainable Construction, UCL** **The UCL Bartlett Faculty of the Built Environment: Considering the system from the perspective of healthcare buildings**
16:50 - 17:15	**John Kelly, Professor of Uro-Oncology, Division of Surgery & Interventional Science, UCL** **The HALO-X platform for detection of adverse events at home during and after treatment**
17:15 – 17:25	**Closing remarks: Professor Geraint Rees, Vice-Provost (Research, Innovation and Global Engagement)**
17:25 – 18:30	**Networking drinks reception**

Session 1

Chair: Daniel Hochhauser

Professor Daniel Hochhauser is Head of the Department of Oncology at the UCL Cancer Institute, Cancer Theme Lead for the NIHR UCLH Biomedical Research Centre, co-chair of the UCL Cancer Domain and a consultant medical oncologist. Following postgraduate medical training in London and Oxford, he was awarded a DPhil at the Institute of Molecular Medicine in Oxford. Subsequently he completed specialist training at the Memorial Sloan-Kettering Cancer Center in New York before appointment as a consultant and senior lecturer in 1996.

Professor Charles Swanton

Professor Charles Swanton FRCP BSc PhD is a clinician scientist, focusing his work on understanding the challenges inherent in the management of metastatic cancer and their drug resistant and incurable nature.

He completed his PhD in 1998 at the Imperial Cancer Research Fund Laboratories on the UCL MBPhD programme before completing his medical oncology and Cancer Research UK (CRUK) funded postdoctoral clinician scientist training in 2008.

Professor Swanton was appointed CRUK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the London Research Institute (now part of the Francis Crick Institute) and consultant medical oncologist at the Royal Marsden Hospital in 2008. He was appointed Fellow of the Royal College of Physicians, Chair in Personalised Cancer Medicine at the UCL Cancer Institute and Consultant Thoracic Medical Oncologist at UCL Hospitals in 2011.

He is the Chief Investigator of the CRUK TRACERx clinical study to decipher lung cancer evolution and is co-director of the CRUK Lung Cancer Centre of Excellence.

Professor Alison Lloyd

Professor Alison Lloyd is currently Director of the LMCB at UCL where she runs the Cell Biogenesis and Tissue Regeneration research group. She studied Biochemistry for her undergraduate studies at UCL, a PhD with Chris Marshall at the ICR in London followed by two postdoctoral fellowships in Strasbourg, France and at the ICRF laboratories in London. In 1998, she started her laboratory at the LMCB at UCL, where she continues to run her research group. She is co-chair of the UCL Cancer Domain, a member of EMBO and a Fellow of the Academy of Medical Sciences.

Dr Maria Secrier

Maria Secrier is an Associate Professor in Computational Cancer Biology at the UCL Genetics Institute in the Department of Genetics, Evolution and Environment. Her research addresses fundamental questions on somatic evolution using cancer as a primary system of investigation, along two main axes: (1) How mutational processes shape cellular plasticity and intrinsic adaptation to stress; (2) How cells co-evolve with their microenvironmental niche to evade therapy and persist in the tissue.

Dr Secrier received her bachelor's degree from Jacobs University (Bremen, Germany) and PhD from the European Molecular Biology Laboratory (EMBL, Heidelberg) and the University of Heidelberg (Germany). Following her PhD she worked on the genomics of oesophageal cancer as a Research Associate at the Cancer Research UK Cambridge Institute under the supervision of Professor Simon Tavare and Professor Rebecca Fitzgerald. She also spent some time in industry, working in the areas of new target identification and immuno-oncology as a Senior Scientist at AstraZeneca.

Dr Kasper Fugger

Kasper Fugger started his career in 2002 as a MSc student in the lab of Drs Jiri Bartek and Jiri Lukas at the Danish Cancer Society, focusing on mechanistic studies of cell cycle regulation and its interplay with DNA repair pathways. In 2005, Kasper pursued his PhD studies in the same lab, employing RNAi as a tool to study synthetic lethality in cancers with deregulated cell cycle control. After completing his PhD in 2009, Kasper continued his postdoc studies in the lab of Claus Sørensen at the Biotech Research and Innovation Centre (Copenhagen), focusing on the DNA replication stress response and its role in maintaining genome stability. In 2014, Kasper moved to Cancer Research UK's Clare Hall Laboratories, prior to its integration with the Francis Crick Institute in 2016. Here, Kasper discovered that targeting the nucleotide metabolic factor, DNPH1, enhances the efficacy of chemotherapy and counteracts resistance mechanisms, and is now a major target for cancer therapy.

In 2022, Kasper established his own lab at the UCL Cancer Institute funded by Cancer Research UK RadNet while continuing as a visiting scientist at the Crick. The major research focus of his lab is how non-canonical nucleotides originating from cellular processes, radiation/carcinogen exposure or recycled from our gut microbiome can alter our genomes and give rise to

human diseases including cancer. Kasper's research is deeply committed to translational science and works closely with industry partners to convert biological discoveries into novel therapeutic strategies.



Dr Marnix Jansen

Marnix Jansen is a consultant gastrointestinal histopathologist at University College Hospital NHS Trust and group leader at UCL Cancer Institute. Dr Jansen trained in the Academic Medical Centre in Amsterdam, the Netherlands and obtained his PhD in the laboratory of Hans Clevers at the Hubrecht Institute for Stem Cell Research. After obtaining a Translational Cancer Research Fellowship awarded by the Dutch Cancer Society (KWF), he moved to UCL Cancer Institute. He has undertaken combined clinical and research training at the pathology departments of Johns Hopkins in Baltimore, USA and the National Cancer Centre Hospital in Tokyo, Japan. The work in his research group focuses on early cancer evolution across the gastrointestinal tract.

Dr Brieuc Lehmann

Brieuc Lehmann is a Lecturer (Assistant Professor) in Statistical Science at UCL. His primary research area is health data science, with a particular focus on statistical methods for health equity. As well as methodological research in statistics, Brieuc has ongoing projects in epidemiology, genomics, clinical trials, and disease risk prediction. He is also co-founder of Data Science for Health Equity (https://www.dsxhe.com), a community-of-interest for academics, healthcare professionals, policymakers, and others working at the intersection of data science and health equity.

Before UCL, Brieuc was a postdoctoral research associate in statistical machine learning at the Big Data Institute and the Department of Statistics at the University of Oxford, working with Prof Chris Holmes and Prof Gil McVean. He also held a Junior Research Fellowship in Statistics at Jesus College, Oxford from September 2019, and was part of the Turing-RSS Health Data Lab from November 2020. Before this, Brieuc undertook a PhD at the MRC Biostatistics Unit, University of Cambridge under the supervision of Dr Simon White, Prof Rik Henson and Dr Linda Geerligs.

Session 2

Chair: Professor Nicholas Greene

Professor Nick Greene is Head of the Developmental Biology and Cancer Department at GOS Institute of Child Health. He has been Professor of Developmental Neurobiology at the Institute since 2013, and his group works on development and disease of the central nervous system.

Professor Tariq Enver

Professor Tariq Enver joined UCL in 2010 as Head of the Department of Cancer Biology and subsequently was appointed Vice Dean Research of the Faculty of Medical Sciences. Professor Enver became the Director of UCL's Cancer Institute in 2013 and is also co-Director of the CRUK UCL Centre, a focal point for cancer research at UCL, bringing together researchers and clinicians from UCL and its partner hospital trusts to accelerate cancer research discoveries. He is the lead for the Cancer Research UK City of London Centre, which brings together world-leading researchers from UCL, King's College London, Queen Mary University of London and the Francis Crick Institute to enable London to become a global centre of excellence for biotherapeutics. He leads the City of London RadNet programme and the CRUK City of London Centre's Radiation Research Unit, which forms part of the National Radnet programme. Additionally he leads the Cancer theme of the Academic Health Sciences Centre, which spans translational cancer activities across UCL and Queen Mary University of London including the Barts Cancer Institute, the London School of Hygiene & Tropical Medicine and the Francis Crick Institute.

Professor Enver studies the genetic circuitry of stem cells, how this may be utilized in the context of transplantation and regenerative medicine and crucially how it is corrupted in the pathogenesis of cancer, particularly in the context of the origins, evolution and targeting of childhood leukaemia. He is a member of the European Molecular Biology Organization (EMBO), the 1000 Talents program in China and Visiting Professor at Lund University in Sweden. He sits on the CRUK Science Committee, Bloodwise Research Committee and is co-director for the Centre for Genomic Regulation in Barcelona.

J.P. Martinez-Barbera

Professor Martinez-Barbera trained as a veterinary surgeon (University of Cordoba, Spain) and obtained his PhD in Biochemistry and Molecular Biology at the University of Cadiz (Spain) in 1995. His postdoctoral career started at Lund University (Sweden) in 1996, where he focused on embryology.

A year later, he moved to the National Institute for Medical Research (London, UK) to continue his interest on brain and pituitary development through the generation and analyses of several mouse models. In 2000, he moved to King's College London as a senior postdoctoral researcher, where he consolidated his expertise on brain development and ES cell targeting technology.

Finally, in 2003, he initiated his independent career at the GOS Institute of Child Health (GOS-ICH; University College London, UK). His research is focused on the study of the role of cellular senescence in paediatric and adult cancers.

Dr Sara Ghorashian

Sara Ghorashian qualified from Oxford University and undertook haematology training at the Hammersmith and Royal Free Hospitals. She obtained a PhD at University College London (UCL) in the use of gene-engineered T cells for cancer immunotherapy.

More recently, her post-doctoral studies at the UCL Great Ormond Street Institute of Child Health involved translation of CD19CAR T cells as therapy for childhood acute lymphoblastic leukaemia (ALL) from bench to bedside. Her research interests are cellular immunotherapy for haematological malignancies and T cell immunobiology.

Dr Ghorashian has clinical interests in paediatric malignant haematology, and leads on cell therapy and research within the department. She is a co-investigator on two CAR T cell studies for ALL, and actively involved in implementing new studies in order to improve outcomes for children with high risk or relapsed haematological malignancies.

Session 3

Professor Rebecca Shipley

Becky Shipley is Professor of Healthcare Engineering at UCL and Chief Research Officer at UCL Partners. Her research combines approaches from the engineering, physical, data and health sciences to better understand disease and injury and to develop health technologies to improve patient outcomes. She works across a range of clinical application areas including cancer, nervous system injury and critical care. Becky was awarded an OBE for her role during the COVID-19 pandemic in developing the UCL-Ventura breathing devices, deployed to over 130 NHS hospitals and used to treat patients in 30 countries.

Professor Karen Page

Karen Page is a Professor of Mathematical Biology at UCL. She studied at Queens' College, Cambridge (MA 1st class, MMath Distinction, 1992-1996). Her DPhil, on the topic of patterning in embryology, was completed in Oxford in 1999. She then went to the Institute for Advanced Study in Princeton as a postdoctoral fellow. There she studied evolutionary game theory and evolutionary dynamics. She joined the Department of Computer Science at UCL in 2001 as a Lecturer in Bioinformatics and subsequently moved to the Department of Mathematics in 2006. She was promoted to Reader in 2010 and Professor in 2015. During her time at UCL, she has worked on applying mathematical models to a variety of areas of biology, and is particularly interested in developmental biology, evolution and cancer.

Dr Steve Harris

Steve Harris is a Principal Research Fellow in Translational Data Science at UCL, an Honorary NHS Critical Care Consultant, and the Chief Research Information Officer at UCLH. He has held fellowships from Wellcome, and the Health Foundation, and won more than £5m in grant funding (UCLH Charity, EPSRC, NIHR/NHS-X) in the last 5 years. He is a co-investigator in the NIHR Patient Safety Research Collaborative, CHIMERA, the Wellcome Innovation Flagship Critical Care Asia, and co-leads the NIHR Health Informatics Collaborative for Critical Care. At UCLH, he led the implementation of the Experimental Medicine Application Platform (EMAP) and FlowEHR that aim to bridge the 'AI chasm', and deliver algorithms and inference to the bedside.

Professor Grant Mills

Professor Grant Mills is a Professor of Healthcare Infrastructure Delivery and Bartlett Faculty Lead for Health at UCL. He researches advanced healthcare infrastructure delivery models, interdisciplinary design and project management. He has been investigator on EPSRC, ESRC, NIHR and IUK research and directly funded by the Department of Health, European Investment Bank and World Health Organization. Recent research has investigated healthcare diagnostic hub design, augmented reality for hospitals delivery, flat-pack modular operating theatre configuration, healthcare infrastructure capital investment and advanced data analytics in AEC production control.

From March 2020 Professor Mills has been the Bartlett Faculty Lead for Health building an international reputation for Bartlett Health-related research, teaching and enterprise. In 2013 he completed his PhD on value in design at Loughborough University, prior to which he worked for AMEC Group Limited (a multi-disciplinary engineering firm) across Innovation and Technology, Design and Value Management departments.

Professor John Kelly

Professor John Kelly is a consultant urological surgeon specialising in robotic surgery for bladder and prostate cancer as well as the lead for the London Cancer Urology Surgery Centre and the robotic surgery programme at UCLH. John is also the professor of uro-oncology at UCL and his research group explore how new therapies for bladder and prostate cancer can improve outcomes for patients.

Professor Kelly is the Clinical Lead for urology at Westmoreland Street Hospital. The department is one the largest in Europe and delivers cutting edge surgery using the latest technologies. The position, working with teams across the many different aspects of urology and leaders in the field is highly rewarding.

He moved to UCLH in 2009 from Cambridge University having worked at Addenbrookes in complex cancer surgery and as a fellow at the Cornell University Hospital, New York. He is known internationally for his pioneering work in robotic surgery and is the director of the Chitra Sethia Minimal Access Centre at UCLH which trains robotic surgeons.

He has been the chairman of the UK National Cancer Research Institute, Bladder Clinical Studies Group and is currently the chairman of the Scientific Committee of The Urology Foundation and holds the Orchid chair of male genito-urinary oncology with the Orchid Charity.

Research Posters

1. Huda Alnufaei

The correlation between Boronophenylalanine (BPA) uptake and cell transporters in various human cell lines.

2. Reem Al-Saadi

Multimodality Detection of Tumour Rupture In Children With Wilms Tumour

3. Elysse Bautista

Unraveling Delays in Lung Cancer Care: Insights and Implications for Patient Navigation Programs in Mexico

4. Cenk Celik

Unravelling Internal and External Regulatory Mechanisms of Cell Cycle Arrest in Breast Cancer

5. Premkamon Chaipanichkul

Effect of hypoxia on Gd-based nanoparticle uptake and distribution in a preclinical spheroid model

6. Matthew Clarke

Predicting Personalised Radio-sensitising Combination Treatments in Non-Small Cell Lung Cancer Using In Silico Modelling

7. Helena Coggan

An agent-based modelling framework to study cell plasticity in non-small cell lung cancer

8. Tishe Coker

The proportion of preclinical models characterising Black patients with prostate cancer and how well they represent the biological features of their disease – a systematic review

9. Laura Donovan

MYC-Driven Recurrent Medulloblastoma and CD74: Targeting the Nexus for Effective Treatment

10. Emily Drabek-Maunder

Pre-treatment evidence of abnormal supratentorial white matter in children with posterior fossa tumours using diffusion MRI

11. Benjamin Draper

Overcoming Tumour Heterogeneity in Medulloblastoma with Dual-Targeting CAR T-cells

12. Peter Embacher

Stochastic modelling of lineage correlations in glioblastoma cells to capture non-genetic heterogeneity

13. Andrei Enica

Informing lung cancer immunoprevention using spatial omics

14. Enzo Giardina

Design of retinoid-responsive toxin gene systems for neuroblastoma treatment

15. Amalia Gjerloev

Using operational research simulation techniques to inform decision making for cancer pathways

16. Priyanka Gupta

Engineering advanced healthcare models for drug testing: Chemotherapy screening on a novel, dynamic, multicompartmental, multicellular pancreatic cancer model

17. Anna-Dimitra Kataki

Mapping the therapeutic efficiency of novel proton beam therapies on advanced multicellular 3D pancreatic cancer models: Towards building better healthcare delivery models

18. Veronika Lachina

Investigating the mechanical changes in the fibroblastic reticular network of tumour-draining lymph nodes using a vertex model

19. Leticia Meneguello

Exploring the role of REXO1 in R-loop biology and cellular response to oncogene-induced replication stress

20. Francesco Moscato

Computational Modelling of ICB Resistance Mechanisms in Metastatic Melanoma

21. Callum Nattress

Multimodal γδ T Cell Cytotoxicity Overcomes Cellular Therapy Reprogramming

22. Callum Oddy

Studying the development and clonal heterogeneity of gastric intestinal metaplasia (GIM) in human biopsy-derived organoids.

23. Shi Pan

Understanding the epithelial-to-mesenchymal transition in cancer with a single-cell language model

24. Stephen Patrick

Improved Tumour Delivery of Iron-Oxide Nanoparticles for Magnetic Hyperthermia Therapy of Melanoma via Ultrasound Guidance and 111In SPECT Quantification

25.Piotr Pawlik

A novel algorithm for deconvolving cancer allele-specific clone copy number and copy number evolution

26. Zofia Piszka

Studying genomic evolution in colonic cell line models of mismatch repair deficiency.

27. Ahmed Rokan

The Evolution of a Transplantable Tumour

28. Hugh Selway-Clarke

In Silico Testing of Hypotheses for the Effect of Smoking on Somatic Evolution in the Healthy Human Lung

29. Daniel Shewring

Harnessing the Lymphoid Tissue Niche to enhance anti-tumour immunity

30. Emmi Suonpera

Screening and early detection to prevent anal cancer (SEPAC): protocol and progress report

31. Vithurran Thavarajah

Spatial characterisation of an explant model of localised prostate cancer

32. Rebecca Todd

An introduction to the TRANSFORM and REFORM projects: Addressing racial inequalities in treatment and survivorship for Black patients with prostate or breast cancer.

33. Yuchen Yang

Advancing Early Cancer Diagnosis: The ADEPTS Study for pancreatic cancer and other pancreaticobiliary disease.

34. Fatimah Zachariah Ali

A platform for quantitative mapping of boron uptake and microdistribution in a preclinical cancer model to inform boron neutron capture therapy (BNCT) drug studies

View Full Poster Abstracts

Poster abstracts are available in full via the below link:

https://www.ucl.ac.uk/research/domains/sites/research_domains/files/cancer_symposium_2024_poster_booklet.pdf

Symposium Sponsors

Major Sponsor: Stratech are not a multi-national super conglomerate biotech company, instead we are family run business dedicated to delivering exceptional product quality with unbeatable technical support. We are so confident that you will LOVE both our products and our technical support that we guarantee all our products with a full money back promise.

Say hello to prices up to 50% less than other suppliers!

We aim to offer high quality research tools at prices so low that as many researchers as possible will be able to afford them.

Our range includes high quality life science reagents, antibodies, fluorescent tools and biochemicals.

Sarstedt is one of the world's leading providers of laboratory and medical equipment, which develops, manufactures and distributes consumables in the field of medicine and research. Our company is known for its 'High quality, High-performance and Made in Germany' products and has an uncompromising commitment to customer requirements.

UCL Translational Research Office (TRO) is an integral part of UCL's biomedical research powerhouse. As an expert team of applied scientists and business developers, we support our researchers in realising their translational ambition by offering strategic advice, funding support, and bridging the gap with industry to help establish collaborations that drive the pipeline of therapeutic, device and diagnostic innovations.

UCL Business Limited (UCLB), is a wholly owned subsidiary of UCL. Working with UCL's world-renowned researchers, faculties and associated hospitals we bring together exceptional ideas, innovations and industry to benefit society and the economy. UCLB's track record includes raising over £1.5 billion in investment for UCL spinouts.

Further Information

Location

- The event will take place in the Kennedy Lecture Theatre, UCL Institute of Child Health (ICH), 30 Guilford Street, London, WC1N 1EH. Please see the accessibility information here. Talks and presentations will take place in the ICH Kennedy Lecture Theatre.
- Posters will be displayed in the ICH Balcony and Winter Garden.
- Lunch and refreshments will be served in the ICH Balcony and Winter Garden - Drinks reception will take place in the ICH Balcony.

Connecting to Wifi

Before you start...

- You must be aware of and abide by the UCL Computing Regulations
- You must be aware of and abide by the JANET Acceptable Use Policy

Figure 1: Welcome to Sky Wi-Fi page



Figure 2: Sky Wi-Fi login and registration page

Instructions

1. Select UCLGuest from your list of available Wi-Fi networks
2. Once connected, open a web browser and refresh your page
3. At the Welcome page (Fig.1) click Go
4. If you already have a The Cloud account, enter your email address and password and click Continue. If you do not have a The Cloud account, click Create Account to register (Fig.2)
5. After you have created a new account you will be connected to UCLGuest. You will also receive an email confirmation with your details.

Having trouble connecting?

For further instructions please see Wi-Fi troubleshooting & known issues.

Venue Layout and Poster Locations

Balcony Area

UCL GOS Institute of Child Health

Winter Garden

UCL GOS Institute of Child Health

- Toilets
- Lifts
- Stairs
- Dining table
- Seating
- Poster Boards (with Poster Number)
- Notice board
- Food station with dietary requirements e.g. gluten free